Listen to the Audio Recording: Click here

Manufacturing quality issues are a leading cause of supply chain disruption for pharmaceuticals. The absence of aligned incentives has forced manufacturers at times to meet minimal manufacturing standards or pull out of certain markets altogether. Transparency and collaboration are key steps to addressing the risk to quality, as shared in this session by various stakeholders from the pharmaceutical supply chain. Learn how suppliers and providers are coming together through the work of the End Drug Shortages Alliance. Plus, hear the latest updates on emerging industry solutions that are exploring ways to measure elements of quality that can lead to greater resiliency in the supply chain.

Learning Objectives:

1. Examine how gaps in quality can negatively impact product availability.

2. Identify how key supply chain stakeholders including suppliers, distributors, IDNs, and GPOs are working together to achieve better transparency, achieve supply readiness and mitigate quality issues.

3. Analyze FDA’s work on the Quality Management Maturity program for pharmaceutical manufacturing sites, and how it can provide improved supply chain insights that can support providers in making informed purchasing decisions leading to enhanced product access and availability.

4. Formulate strategies for your organization can better position itself to provide better patient safety and quality of care.